Elisabeth Picou

BCI Pharma SAS engages in research and development in biotechnology. Its kinase platform is based on a new chemotype with phys-chem properties, able to explore a new chemical space for treating CNS, inflammation, cancer and metabolic diseases. The firm also offers medicinal chemistry, HTS platform and consultancy services. The company was founded by Elisabeth Picou and Dominique Surleraux in March 2013 and is headquartered in Grabels, France.

BCI Pharma SAS engages in research and development in biotechnology. Its kinase platform is based on a new chemotype with phys-chem properties, able to explore a new chemical space for treating CNS, inflammation, cancer and metabolic diseases. The firm also offers medicinal chemistry, HTS platform and consultancy services. The company was founded by Elisabeth Picou and Dominique Surleraux in March 2013 and is headquartered in Grabels, France.

BCI Pharma SAS engages in research and development in biotechnology. Its kinase platform is based on a new chemotype with phys-chem properties, able to explore a new chemical space for treating CNS, inflammation, cancer and metabolic diseases. The firm also offers medicinal chemistry, HTS platform and consultancy services. The company was founded by Elisabeth Picou and Dominique Surleraux in March 2013 and is headquartered in Grabels, France.

BCI Pharma SAS engages in research and development in biotechnology. Its kinase platform is based on a new chemotype with phys-chem properties, able to explore a new chemical space for treating CNS, inflammation, cancer and metabolic diseases. The firm also offers medicinal chemistry, HTS platform and consultancy services. The company was founded by Elisabeth Picou and Dominique Surleraux in March 2013 and is headquartered in Grabels, France.

BCI Pharma SAS engages in research and development in biotechnology. Its kinase platform is based on a new chemotype with phys-chem properties, able to explore a new chemical space for treating CNS, inflammation, cancer and metabolic diseases. The firm also offers medicinal chemistry, HTS platform and consultancy services. The company was founded by Elisabeth Picou and Dominique Surleraux in March 2013 and is headquartered in Grabels, France.